Showing results (291-300 of 395) with videos related to
Sort By:
Pageof 40
The New England Journal of Medicine|January 10, 2014
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditionsValentin Goede, Kirsten Fischer, Raymonde Busch, et al.The Lancet. Haematology|August 2, 2016
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trialGerald Illerhaus, Benjamin Kasenda, Gabriele Ihorst, et al.Nature Medicine|December 9, 2023
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trialOthman Al-Sawaf, Rudy Ligtvoet, Sandra Robrecht, et al.The Lancet. Haematology|September 17, 2017
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 studyAnna Maria Fink, Jasmin Bahlo, Sandra Robrecht, et al.The Lancet. Oncology|February 1, 2017
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trialAndrew D Zelenetz, Jacqueline C Barrientos, Jennifer R Brown, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.Blood|April 15, 2024
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trialMoritz Fürstenau, Adam Giza, Jonathan Weiss, et al.Immunity|December 8, 2021
Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunityBola S Hanna, Laura Llaó-Cid, Murat Iskar, et al.Plos Genetics|April 18, 2013
Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kBAngela Garding, Nupur Bhattacharya, Rainer Claus, et al.Haematologica|February 29, 2020
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trialPaula Cramer, Julia V Tresckow, Sandra Robrecht, et al.Pageof 40